Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Journal of Neurology
Published in: Journal of Neurology 2/2024

Open Access 06-10-2023 | Progressive Supranuclear Palsy | Original Communication

The comorbidity and co-medication profile of patients with progressive supranuclear palsy

Authors: Stephan Greten, Florian Wegner, Ida Jensen, Lea Krey, Sophia Rogozinski, Meret Fehring, Johanne Heine, Johanna Doll-Lee, Monika Pötter-Nerger, Molly Zeitzschel, Keno Hagena, David J. Pedrosa, Carsten Eggers, Katrin Bürk, Claudia Trenkwalder, Inga Claus, Tobias Warnecke, Patrick Süß, Jürgen Winkler, Doreen Gruber, Florin Gandor, Daniela Berg, Steffen Paschen, Joseph Classen, Elmar H. Pinkhardt, Jan Kassubek, Wolfgang H. Jost, Lars Tönges, Andrea A. Kühn, Johannes Schwarz, Oliver Peters, Eman Dashti, Josef Priller, Eike J. Spruth, Patricia Krause, Annika Spottke, Anja Schneider, Aline Beyle, Okka Kimmich, Markus Donix, Robert Haussmann, Moritz Brandt, Elisabeth Dinter, Jens Wiltfang, Björn H. Schott, Inga Zerr, Mathias Bähr, Katharina Buerger, Daniel Janowitz, Robert Perneczky, Boris-Stephan Rauchmann, Endy Weidinger, Johannes Levin, Sabrina Katzdobler, Emrah Düzel, Wenzel Glanz, Stefan Teipel, Ingo Kilimann, Johannes Prudlo, Thomas Gasser, Kathrin Brockmann, Daniel C. Hoffmann, Thomas Klockgether, Olaf Krause, Johannes Heck, Günter U. Höglinger, Martin Klietz

Published in: Journal of Neurology | Issue 2/2024

Login to get access

Abstract

Background

Progressive supranuclear palsy (PSP) is usually diagnosed in elderly. Currently, little is known about comorbidities and the co-medication in these patients.

Objectives

To explore the pattern of comorbidities and co-medication in PSP patients according to the known different phenotypes and in comparison with patients without neurodegenerative disease.

Methods

Cross-sectional data of PSP and patients without neurodegenerative diseases (non-ND) were collected from three German multicenter observational studies (DescribePSP, ProPSP and DANCER). The prevalence of comorbidities according to WHO ICD-10 classification and the prevalence of drugs administered according to WHO ATC system were analyzed. Potential drug–drug interactions were evaluated using AiDKlinik®.

Results

In total, 335 PSP and 275 non-ND patients were included in this analysis. The prevalence of diseases of the circulatory and the nervous system was higher in PSP at first level of ICD-10. Dorsopathies, diabetes mellitus, other nutritional deficiencies and polyneuropathies were more frequent in PSP at second level of ICD-10. In particular, the summed prevalence of cardiovascular and cerebrovascular diseases was higher in PSP patients. More drugs were administered in the PSP group leading to a greater percentage of patients with polypharmacy. Accordingly, the prevalence of potential drug–drug interactions was higher in PSP patients, especially severe and moderate interactions.

Conclusions

PSP patients possess a characteristic profile of comorbidities, particularly diabetes and cardiovascular diseases. The eminent burden of comorbidities and resulting polypharmacy should be carefully considered when treating PSP patients.
Literature
1.
Bower JH, Maraganore DM, McDonnell SK, Rocca WA (1997) Incidence of progressive supranuclear palsy and multiple system atrophy in Olmsted County, Minnesota, 1976 to 1990. Neurology 49:1284–1288PubMedCrossRef
2.
Respondek G, Stamelou M, Kurz C et al (2014) The phenotypic spectrum of progressive supranuclear palsy: a retrospective multicenter study of 100 definite cases. Mov Disord 29:1758–1766PubMedCrossRef
3.
Kwasny MJ, Oleske DM, Zamudio J, Diegidio R, Höglinger GU (2021) Clinical features observed in general practice associated with the subsequent diagnosis of progressive supranuclear palsy. Front Neurol 12:637176PubMedPubMedCentralCrossRef
4.
Zella MAS, Bartig D, Herrmann L, Respondek G, Höglinger G, Gold R, Woitalla D, Krogias C, Tönges L (2020) Hospitalization rates and comorbidities in patients with progressive supranuclear palsy in Germany from 2010 to 2017. J Clin Med 9:E2454CrossRef
5.
Rabadia SV, Litvan I, Juncos J et al (2019) Hypertension and progressive supranuclear palsy. Parkinsonism Relat Disord 66:166–170PubMedCrossRef
6.
Lamb R, Rohrer JD, Lees AJ, Morris HR (2016) Progressive supranuclear palsy and corticobasal degeneration: pathophysiology and treatment options. Curr Treat Options Neurol 18:42PubMedPubMedCentralCrossRef
7.
8.
9.
Midão L, Giardini A, Menditto E, Kardas P, Costa E (2018) Polypharmacy prevalence among older adults based on the survey of health, ageing and retirement in Europe. Arch Gerontol Geriatr 78:213–220PubMedCrossRef
10.
11.
Johnell K, Klarin I (2007) The relationship between number of drugs and potential drug-drug interactions in the elderly: a study of over 600,000 elderly patients from the Swedish Prescribed Drug Register. Drug Saf 30:911–918PubMedCrossRef
12.
Wastesson JW, Morin L, Tan ECK, Johnell K (2018) An update on the clinical consequences of polypharmacy in older adults: a narrative review. Expert Opin Drug Saf 17:1185–1196PubMedCrossRef
13.
Leelakanok N, Holcombe AL, Lund BC, Gu X, Schweizer ML (2017) Association between polypharmacy and death: a systematic review and meta-analysis. J Am Pharm Assoc 57:729-738.e10CrossRef
14.
Piot I, Schweyer K, Respondek G et al (2020) The progressive supranuclear palsy clinical deficits scale. Mov Disord 35:650–661PubMedCrossRef
15.
Respondek G, Höglinger GU (2021) DescribePSP and ProPSP: German multicenter networks for standardized prospective collection of clinical data, imaging data, and biomaterials of patients with progressive supranuclear palsy. Front Neurol 12:644064PubMedPubMedCentralCrossRef
16.
Höglinger GU, Respondek G, Stamelou M et al (2017) Clinical diagnosis of progressive supranuclear palsy: the movement disorder society criteria: MDS Clinical Diagnostic Criteria for PSP. Mov Disord 32:853–864PubMedPubMedCentralCrossRef
17.
Grimm M-J, Respondek G, Stamelou M et al (2019) How to apply the movement disorder society criteria for diagnosis of progressive supranuclear palsy. Mov Disord 34:1228–1232PubMedPubMedCentralCrossRef
18.
Schade S, Mollenhauer B, Trenkwalder C (2020) Levodopa equivalent dose conversion factors: an updated proposal including opicapone and safinamide. Mov Disord Clin Pract 7:343–345PubMedPubMedCentralCrossRef
19.
Hecht T, Bundscherer AC, Lassen CL, Lindenberg N, Graf BM, Ittner K-P, Wiese CHR (2015) The expenditure of computer-related worktime using clinical decision support systems in chronic pain therapy. BMC Anesthesiol 15:113PubMedPubMedCentralCrossRef
20.
Seidling HM, Klein U, Schaier M, Czock D, Theile D, Pruszydlo MG, Kaltschmidt J, Mikus G, Haefeli WE (2014) What, if all alerts were specific - estimating the potential impact on drug interaction alert burden. Int J Med Inform 83:285–291PubMedCrossRef
21.
Bertsche T, Pfaff J, Schiller P, Kaltschmidt J, Pruszydlo MG, Stremmel W, Walter-Sack I, Haefeli WE, Encke J (2010) Prevention of adverse drug reactions in intensive care patients by personal intervention based on an electronic clinical decision support system. Intensive Care Med 36:665–672PubMedCrossRef
22.
Sieber CC (2007) The elderly patient–who is that? Internist (Berl) 48(1190):1192–1194
23.
Papapetropoulos S, Singer C, McCorquodale D, Gonzalez J, Mash DC (2005) Cause, seasonality of death and co-morbidities in progressive supranuclear palsy (PSP). Parkinsonism Relat Disord 11:459–463PubMedCrossRef
24.
Tamayo T, Brinks R, Hoyer A, Kuß OS, Rathmann W (2016) The prevalence and incidence of diabetes in Germany. Dtsch Arztebl Int 113:177–182PubMedPubMedCentral
25.
Busch MA, Schienkiewitz A, Nowossadeck E, Gößwald A (2013) Prävalenz des Schlaganfalls bei Erwachsenen im Alter von 40 bis 79 Jahren in Deutschland: Ergebnisse der Studie zur Gesundheit Erwachsener in Deutschland (DEGS1). Bundesgesundheitsbl 56:656–660CrossRef
26.
Zhang Y, Moran AE (2017) Trends in the prevalence, awareness, treatment, and control of hypertension among young adults in the United States, 1999 to 2014. Hypertension 70:736–742PubMedCrossRef
27.
Baglietto-Vargas D, Shi J, Yaeger DM, Ager R, LaFerla FM (2016) Diabetes and Alzheimer’s disease crosstalk. Neurosci Biobehav Rev 64:272–287PubMedCrossRef
28.
Potashkin J, Huang X, Becker C, Chen H, Foltynie T, Marras C (2020) Understanding the links between cardiovascular disease and Parkinson’s disease. Mov Disord 35:55–74PubMedCrossRef
29.
30.
Liu Y, Xue L, Zhang Y, Xie A (2020) Association between stroke and parkinson’s disease: a meta-analysis. J Mol Neurosci 70:1169–1176PubMedCrossRef
31.
Jecmenica Lukic M, Kurz C, Respondek G et al (2020) Copathology in progressive supranuclear palsy: does it matter? Mov Disord 35:984–993PubMedCrossRef
32.
Leszek J, Sochocka M, Gąsiorowski K (2012) Vascular factors and epigenetic modifications in the pathogenesis of Alzheimer’s disease. J Neurol Sci 323:25–32PubMedCrossRef
33.
Hughes AJ, Daniel SE, Kilford L, Lees AJ (1992) Accuracy of clinical diagnosis of idiopathic Parkinson’s disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 55:181–184PubMedPubMedCentralCrossRef
34.
Uyar M, Lezius S, Buhmann C, Pötter-Nerger M, Schulz R, Meier S, Gerloff C, Kuhle J, Choe C-U (2022) Diabetes, glycated hemoglobin (HbA1c), and neuroaxonal damage in Parkinson’s Disease (MARK-PD Study). Mov Disord 37:1299–1304PubMedCrossRef
35.
Komici K, Femminella GD, Bencivenga L, Rengo G, Pagano G (2021) Diabetes mellitus and Parkinson’s Disease: a systematic review and meta-analyses. JPD 11:1585–1596PubMedCrossRef
36.
37.
De Pablo-Fernandez E, Goldacre R, Pakpoor J, Noyce AJ, Warner TT (2018) Association between diabetes and subsequent Parkinson disease: a record-linkage cohort study. Neurology 91:e139–e142PubMedCrossRef
38.
Aamodt WW, Waligorska T, Shen J et al (2021) Neurofilament light chain as a biomarker for cognitive decline in Parkinson Disease. Mov Disord 36:2945–2950PubMedPubMedCentralCrossRef
39.
Niemann L, Lezius S, Maceski A, Leppert D, Englisch C, Schwedhelm E, Zeller T, Gerloff C, Kuhle J, Choe C-U (2021) Serum neurofilament is associated with motor function, cognitive decline and subclinical cardiac damage in advanced Parkinson’s disease (MARK-PD). Parkinsonism Relat Disord 90:44–48PubMedCrossRef
40.
Gejl M, Gjedde A, Egefjord L et al (2016) In Alzheimer’s disease, 6-month treatment with GLP-1 analog prevents decline of brain glucose metabolism: randomized, placebo-controlled. Double-Blind Clin Trial Front Aging Neurosci 8:108
41.
Imfeld P, Bodmer M, Jick SS, Meier CR (2012) Metformin, other antidiabetic drugs, and risk of Alzheimer’s disease: a population-based case-control study. J Am Geriatr Soc 60:916–921PubMedCrossRef
42.
Kim B, Backus C, Oh S, Feldman EL (2013) Hyperglycemia-induced tau cleavage in vitro and in vivo: a possible link between diabetes and Alzheimer’s disease. J Alzheimers Dis 34:727–739PubMedPubMedCentralCrossRef
43.
Huang R, Tian S, Zhang H, Zhu W, Wang S (2020) Chronic hyperglycemia induces tau hyperphosphorylation by downregulating OGT-involved O-GlcNAcylation in vivo and in vitro. Brain Res Bull 156:76–85PubMedCrossRef
44.
45.
Custodio N, Montesinos R, Lira D, Herrera-Pérez E, Bardales Y, Valeriano-Lorenzo L (2017) Mixed dementia: a review of the evidence. Dement Neuropsychol 11:364–370PubMedPubMedCentralCrossRef
46.
47.
Kapasi A, Yu L, Petyuk V, Arfanakis K, Bennett DA, Schneider JA (2022) Association of small vessel disease with tau pathology. Acta Neuropathol 143:349–362PubMedPubMedCentralCrossRef
48.
Kapasi A, Leurgans SE, Arvanitakis Z, Barnes LL, Bennett DA, Schneider JA (2021) Aβ (Amyloid Beta) and Tau Tangle Pathology Modifies the Association between small vessel disease and cortical microinfarcts. Stroke 52:1012–1021PubMedPubMedCentralCrossRef
49.
Chiti F, Dobson CM (2017) Protein misfolding, amyloid formation, and human disease: a summary of progress over the last decade. Annu Rev Biochem 86:27–68PubMedCrossRef
50.
Chaudhuri TK, Paul S (2006) Protein-misfolding diseases and chaperone-based therapeutic approaches. FEBS J 273:1331–1349PubMedCrossRef
51.
Welch WJ (2004) Role of quality control pathways in human diseases involving protein misfolding. Semin Cell Dev Biol 15:31–38PubMedCrossRef
52.
Brehme M, Voisine C, Rolland T et al (2014) A chaperome subnetwork safeguards proteostasis in aging and neurodegenerative disease. Cell Rep 9:1135–1150PubMedPubMedCentralCrossRef
53.
McKinnon C, Tabrizi SJ (2014) The ubiquitin-proteasome system in neurodegeneration. Antioxid Redox Signal 21:2302–2321PubMedCrossRef
54.
Dias BM, Santos FSD, Reis AMM (2019) Potential drug interactions in drug therapy prescribed for older adults at hospital discharge: cross-sectional study. Sao Paulo Med J 137:369–378PubMedPubMedCentralCrossRef
55.
Greten S, Müller-Funogea JI, Wegner F, Höglinger GU, Simon N, Junius-Walker U, Gerbel S, Krause O, Klietz M (2021) Drug safety profiles in geriatric patients with Parkinson’s disease using the FORTA (Fit fOR The Aged) classification: results from a mono-centric retrospective analysis. J Neural Transm (Vienna) 128:49–60PubMedCrossRef
56.
Müller-Rebstein S, Trenkwalder C, Ebentheuer J, Oertel WH, Culmsee C, Höglinger GU (2017) Drug safety analysis in a real-life cohort of Parkinson’s disease patients with polypharmacy. CNS Drugs 31:1093–1102PubMedCrossRef
57.
Sánchez-Arenas R, Sánchez-García S, García-Peña C, García-Gonzàlez JJ, Rivera-García BE, Juárez-Cedillo T (2012) Drug-drug interactions at hospital admission in geriatric patients in a single facility: a retrospective study. Int J Clin Pharmacol Ther 50:426–430PubMedCrossRef
58.
Hong WK, Mauer P, Hochman R, Caslowitz JG, Paraskos JA (1974) Amitriptyline cardiotoxicity. Chest 66:304–306PubMedCrossRef
59.
Johannes CB, Varas-Lorenzo C, McQuay LJ, Midkiff KD, Fife D (2010) Risk of serious ventricular arrhythmia and sudden cardiac death in a cohort of users of domperidone: a nested case-control study. Pharmacoepidemiol Drug Saf 19:881–888PubMedCrossRef
60.
van Noord C, Dieleman JP, van Herpen G, Verhamme K, Sturkenboom MCJM (2010) Domperidone and ventricular arrhythmia or sudden cardiac death: a population-based case-control study in the Netherlands. Drug Saf 33:1003–1014PubMedCrossRef
61.
62.
Prieto-García L, Pericacho M, Sancho-Martínez SM, Sánchez Á, Martínez-Salgado C, López-Novoa JM, López-Hernández FJ (2016) Mechanisms of triple whammy acute kidney injury. Pharmacol Ther 167:132–145PubMedCrossRef
63.
Harężlak T, Religioni U, Szymański FM, Hering D, Barańska A, Neumann-Podczaska A, Allan M, Merks P (2022) Drug interactions affecting kidney function: beware of health threats from triple whammy. Adv Ther 39:140–147PubMedCrossRef
64.
Lapi F, Azoulay L, Yin H, Nessim SJ, Suissa S (2013) Concurrent use of diuretics, angiotensin converting enzyme inhibitors, and angiotensin receptor blockers with non-steroidal anti-inflammatory drugs and risk of acute kidney injury: nested case-control study. BMJ 346:e8525PubMedPubMedCentralCrossRef
65.
Clark HM, Stierwalt JAG, Tosakulwong N, Botha H, Ali F, Whitwell JL, Josephs KA (2020) Dysphagia in progressive supranuclear palsy. Dysphagia 35:667–676PubMedCrossRef
66.
Thiyagalingam S, Kulinski AE, Thorsteinsdottir B, Shindelar KL, Takahashi PY (2021) Dysphagia in older adults. Mayo Clin Proc 96:488–497PubMedCrossRef
67.
Moura CS, Prado NM, Belo NO, Acurcio FA (2012) Evaluation of drug–drug interaction screening software combined with pharmacist intervention. Int J Clin Pharm 34:547–552PubMedCrossRef
Metadata
Title
The comorbidity and co-medication profile of patients with progressive supranuclear palsy
Authors
Stephan Greten
Florian Wegner
Ida Jensen
Lea Krey
Sophia Rogozinski
Meret Fehring
Johanne Heine
Johanna Doll-Lee
Monika Pötter-Nerger
Molly Zeitzschel
Keno Hagena
David J. Pedrosa
Carsten Eggers
Katrin Bürk
Claudia Trenkwalder
Inga Claus
Tobias Warnecke
Patrick Süß
Jürgen Winkler
Doreen Gruber
Florin Gandor
Daniela Berg
Steffen Paschen
Joseph Classen
Elmar H. Pinkhardt
Jan Kassubek
Wolfgang H. Jost
Lars Tönges
Andrea A. Kühn
Johannes Schwarz
Oliver Peters
Eman Dashti
Josef Priller
Eike J. Spruth
Patricia Krause
Annika Spottke
Anja Schneider
Aline Beyle
Okka Kimmich
Markus Donix
Robert Haussmann
Moritz Brandt
Elisabeth Dinter
Jens Wiltfang
Björn H. Schott
Inga Zerr
Mathias Bähr
Katharina Buerger
Daniel Janowitz
Robert Perneczky
Boris-Stephan Rauchmann
Endy Weidinger
Johannes Levin
Sabrina Katzdobler
Emrah Düzel
Wenzel Glanz
Stefan Teipel
Ingo Kilimann
Johannes Prudlo
Thomas Gasser
Kathrin Brockmann
Daniel C. Hoffmann
Thomas Klockgether
Olaf Krause
Johannes Heck
Günter U. Höglinger
Martin Klietz
Publication date
06-10-2023
Publisher
Springer Berlin Heidelberg
Published in
Journal of Neurology / Issue 2/2024
Print ISSN: 0340-5354
Electronic ISSN: 1432-1459
DOI
https://doi.org/10.1007/s00415-023-12006-4

Other articles of this Issue 2/2024

Journal of Neurology 2/2024 Go to the issue

Short Commentary

Rasmussen’s syndrome treated with anakinra

Original Communication

Emotional burden among MS patients: associations between specific chronic pain diagnoses and psychological features

Original Communication

Transcriptomic analysis reveals associations of blood-based A-to-I editing with Parkinson’s disease

Original Communication

The value of routine blood work-up in clinical stratification and prognosis of patients with amyotrophic lateral sclerosis

Review

Relationships between intracranial arterial dolichoectasia and small vessel disease in patients with ischaemic stroke: a systematic review and meta-analysis

Original Communication

Ocrelizumab exposure in relapsing–remitting multiple sclerosis: 10-year analysis of the phase 2 randomized clinical trial and its extension